577 |
Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG) |
Duk-Woo Park |
Jul. 25. 08 |
576 |
Late Clinical Outcomes After DES |
Jeffrey J. Popma |
Jul. 18. 08 |
575 |
Endothelial Progenitor Cell Capture Technology and Beyond |
Michael Kutryk |
Jul. 18. 08 |
574 |
TAXUS 'On-Label' Clinical Outcomes & 'Off-Label' Experiences in Real World |
Keith D. Dawkins |
Jul. 18. 08 |
573 |
Clinical Experience with the Xience-V Stent |
Jacques J. Koolen |
Jul. 18. 08 |
572 |
The Endeavor Program: Update 2008 |
Mitchell W. Krucoff |
Jul. 18. 08 |
571 |
Overview of the Sirolimus Eluting Stent Program: A Spectrum of Safety and Efficacy Among Differing DES |
David E. Kandzari |
Jul. 18. 08 |
570 |
Triple Antiplatelet Therapy Significantly Reduced Stent Thrombosis After Drug-Eluting Stent Implantation |
Seong-Wook Park |
Jul. 18. 08 |
569 |
Optimizing Antiplatelet Therapy in PCI/ Antiplatelet Therapy After PCI: How Much and How Long? |
Adnan Kastrati |
Jul. 18. 08 |
568 |
DES Thrombosis How Long Patients Will Be on Dual Antiplatelet Therapy? |
Ron Waksman |
Jul. 18. 08 |